A detailed history of Affinity Asset Advisors, LLC transactions in Next Cure, Inc. stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 2,302,598 shares of NXTC stock, worth $2.16 Million. This represents 0.54% of its overall portfolio holdings.

Number of Shares
2,302,598
Previous 1,687,955 36.41%
Holding current value
$2.16 Million
Previous $2.68 Million 17.55%
% of portfolio
0.54%
Previous 0.37%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1.33 - $1.78 $817,475 - $1.09 Million
614,643 Added 36.41%
2,302,598 $3.15 Million
Q2 2024

Aug 14, 2024

BUY
$1.17 - $2.49 $384,834 - $819,005
328,918 Added 24.2%
1,687,955 $2.68 Million
Q1 2024

May 14, 2024

BUY
$1.13 - $2.23 $1.54 Million - $3.03 Million
1,359,037 New
1,359,037 $3.03 Million

Others Institutions Holding NXTC

About NextCure, Inc.


  • Ticker NXTC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,748,800
  • Market Cap $26.1M
  • Description
  • NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...
More about NXTC
Track This Portfolio

Track Affinity Asset Advisors, LLC Portfolio

Follow Affinity Asset Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Asset Advisors, LLC with notifications on news.